Jazz Pharmaceuticals JAZZ Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's total debt?
- Jazz Pharmaceuticals (JAZZ) reported total debt of $5.4B in Q1 2026.
- How has Jazz Pharmaceuticals's total debt changed year-over-year?
- Jazz Pharmaceuticals's total debt decreased by 0.1% year-over-year, from $5.41B to $5.4B.
- What is the long-term trend for Jazz Pharmaceuticals's total debt?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total debt has grown at a 19.3% compound annual growth rate (CAGR), from $2.25B to $5.43B.
- What does total debt mean?
- The total amount of money a company owes to lenders, banks, and lessors.
- How do you interpret total debt?
- An increase in total debt may signal aggressive expansion or acquisition activity, while a decrease indicates deleveraging and improved balance sheet health. High levels of debt relative to cash flow can increase financial risk and interest expense burdens.
- How does total debt compare across companies?
- Biopharmaceutical companies often carry significant debt loads to fund R&D and large-scale acquisitions, making it essential to compare debt levels against EBITDA or total equity to assess solvency relative to industry peers.